TY  - JOUR
AU  - Baldus, O.
AU  - Waser, R.
TI  - Experimental and numerical investigations of heat transport and crystallization kinetics in laser-induced modification of barium strontium titanate thin films
JO  - Applied physics / A
VL  - 80
SN  - 0947-8396
CY  - Berlin
PB  - Springer
M1  - PreJuSER-49726
SP  - 1553
PY  - 2005
N1  - Record converted from VDB: 12.11.2012
AB  - Venous thromboembolism is treated with unfractionated heparin or low-molecular-weight heparin, followed by a vitamin K antagonist. We investigated the potential use of idraparinux, a long-acting inhibitor of activated factor X, as a substitute for standard therapy.We conducted two randomized, open-label noninferiority trials involving 2904 patients with deep-vein thrombosis and 2215 patients with pulmonary embolism to compare the efficacy and safety of idraparinux versus standard therapy. Patients received either subcutaneous idraparinux (2.5 mg once weekly) or a heparin followed by an adjusted-dose vitamin K antagonist for either 3 or 6 months. The primary efficacy outcome was the 3-month incidence of symptomatic recurrent venous thromboembolism (nonfatal or fatal).In the study of patients with deep venous thrombosis, the incidence of recurrence at day 92 was 2.9% in the idraparinux group as compared with 3.0% in the standard-therapy group (odds ratio, 0.98; 95% confidence interval [CI], 0.63 to 1.50), a result that satisfied the prespecified noninferiority requirement. At 6 months, the hazard ratio for idraparinux was 1.01. The rates of clinically relevant bleeding at day 92 were 4.5% in the idraparinux group and 7.0% in the standard-therapy group (P=0.004). At 6 months, bleeding rates were similar. In the study of patients with pulmonary embolism, the incidence of recurrence at day 92 was 3.4% in the idraparinux group and 1.6% in the standard-therapy group (odds ratio, 2.14; 95% CI, 1.21 to 3.78), a finding that did not meet the noninferiority requirement.In patients with deep venous thrombosis, once-weekly subcutaneous idraparinux for 3 or 6 months had an efficacy similar to that of heparin plus a vitamin K antagonist. However, in patients with pulmonary embolism, idraparinux was less efficacious than standard therapy. (ClinicalTrials.gov numbers, NCT00067093 [ClinicalTrials.gov] and NCT00062803 [ClinicalTrials.gov].).
KW  - Anticoagulants: adverse effects
KW  - Anticoagulants: therapeutic use
KW  - Female
KW  - Follow-Up Studies
KW  - Hemorrhage: chemically induced
KW  - Heparin: adverse effects
KW  - Heparin: therapeutic use
KW  - Humans
KW  - Incidence
KW  - Male
KW  - Middle Aged
KW  - Oligosaccharides: adverse effects
KW  - Oligosaccharides: therapeutic use
KW  - Pulmonary Embolism: drug therapy
KW  - Pulmonary Embolism: mortality
KW  - Recurrence
KW  - Treatment Outcome
KW  - Venous Thrombosis: drug therapy
KW  - Venous Thrombosis: mortality
KW  - Vitamin K: antagonists & inhibitors
KW  - Anticoagulants (NLM Chemicals)
KW  - Oligosaccharides (NLM Chemicals)
KW  - idraparinux (NLM Chemicals)
KW  - Vitamin K (NLM Chemicals)
KW  - Heparin (NLM Chemicals)
KW  - J (WoSType)
LB  - PUB:(DE-HGF)16
C6  - pmid:17855670
UR  - <Go to ISI:>//WOS:000227908400030
DO  - DOI:10.1007/s00339-004-2904-7
UR  - https://juser.fz-juelich.de/record/49726
ER  -